Id: acc3289
Group: 2sens
Protein: STAT3
Gene Symbol: STAT3
Protein Id: P40763
Protein Name: STAT3_HUMAN
PTM: phosphorylation
Site: unclear
Site Sequence:
Disease Category: Endocrine and metabolic diseases
Disease: Insulin Resistance
Disease Subtype:
Disease Cellline: HUVEC
Disease Info:
Drug: miR-492
Drug Info: "miR-492 is a type of microRNA, which may play regulatory roles in various biological processes."
Effect: modulate
Effect Info: miR-492 downregulates signaling pathways such as STAT3 phosphorylation and ameliorates high glucose-induced insulin resistance and atherosclerosis.
Note: Non-conventional drugs
Score: 3.0
Pubmed(PMID): 24526524
Sentence Index:
Sentence:

Sequence & Structure:

MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSNTIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMELTSECATSPM

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
STAT3 DANVATIRSEN STAT-3 mRNA 3'UTR antisense inhibitor 2 Recruiting head and neck squamous cell carcinoma ClinicalTrials
STAT3 DANVATIRSEN STAT-3 mRNA 3'UTR antisense inhibitor 2 Active, not recruiting non-small cell lung carcinoma ClinicalTrials
STAT3 DANVATIRSEN STAT-3 mRNA 3'UTR antisense inhibitor 2 Completed non-small cell lung carcinoma ClinicalTrials
STAT3 DANVATIRSEN STAT-3 mRNA 3'UTR antisense inhibitor 1 Completed hepatocellular carcinoma ClinicalTrials
STAT3 DANVATIRSEN STAT-3 mRNA 3'UTR antisense inhibitor 1 Active, not recruiting head and neck squamous cell carcinoma ClinicalTrials
STAT3 DANVATIRSEN STAT-3 mRNA 3'UTR antisense inhibitor 1 Completed diffuse large B-cell lymphoma ClinicalTrials
ClinicalTrials
STAT3 DANVATIRSEN STAT-3 mRNA 3'UTR antisense inhibitor 1 Active, not recruiting neoplasm ClinicalTrials
STAT3 DANVATIRSEN STAT-3 mRNA 3'UTR antisense inhibitor 1 Active, not recruiting non-small cell lung carcinoma ClinicalTrials
STAT3 DANVATIRSEN STAT-3 mRNA 3'UTR antisense inhibitor 1 Completed non-Hodgkins lymphoma ClinicalTrials
STAT3 DANVATIRSEN STAT-3 mRNA 3'UTR antisense inhibitor 1 Active, not recruiting urinary bladder cancer ClinicalTrials
STAT3 DANVATIRSEN STAT-3 mRNA 3'UTR antisense inhibitor 1 Completed cancer ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

STAT3-Ser701
Cancer Intensity
BRCA 0.628
COAD
HGSC
ccRCC
GBM -0.869
HNSC
LUAD 0.536
LUSC
non_ccRCC 0.136
PDAC -1.53
UCEC 1.097
STAT3-Ser718
Cancer Intensity
BRCA
COAD 0.872
HGSC
ccRCC -1.092
GBM
HNSC 0.22
LUAD
LUSC
non_ccRCC
PDAC
UCEC
STAT3-Ser719
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.014
HNSC
LUAD -1.007
LUSC
non_ccRCC
PDAC
UCEC 0.993
STAT3-Ser726
Cancer Intensity
BRCA
COAD 0.434
HGSC -1.719
ccRCC -0.023
GBM
HNSC 0.641
LUAD
LUSC 0.667
non_ccRCC
PDAC
UCEC
STAT3-Ser727
Cancer Intensity
BRCA 1.74
COAD
HGSC
ccRCC
GBM -1.099
HNSC
LUAD -0.272
LUSC
non_ccRCC -0.473
PDAC 0.531
UCEC -0.428
STAT3-Thr713
Cancer Intensity
BRCA
COAD 0.801
HGSC -1.677
ccRCC -0.148
GBM
HNSC 0.539
LUAD
LUSC 0.484
non_ccRCC
PDAC
UCEC
STAT3-Thr714
Cancer Intensity
BRCA 0.773
COAD
HGSC
ccRCC
GBM 0.51
HNSC
LUAD -1.5
LUSC
non_ccRCC 1.028
PDAC -0.908
UCEC 0.096
STAT3-Thr715
Cancer Intensity
BRCA
COAD 0.468
HGSC -1.459
ccRCC 0.21
GBM
HNSC 0.78
LUAD
LUSC
non_ccRCC
PDAC
UCEC
STAT3-Thr716
Cancer Intensity
BRCA
COAD 1.179
HGSC -1.795
ccRCC -0.306
GBM 0.781
HNSC 0.528
LUAD -0.6
LUSC
non_ccRCC
PDAC
UCEC 0.212
STAT3-Thr717
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 1.093
HNSC
LUAD -0.224
LUSC
non_ccRCC
PDAC
UCEC -0.869
STAT3-Thr720
Cancer Intensity
BRCA
COAD 0.825
HGSC
ccRCC -1.112
GBM
HNSC 0.287
LUAD
LUSC
non_ccRCC
PDAC
UCEC
STAT3-Thr721
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.707
HNSC
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
STAT3-Tyr704
Cancer Intensity
BRCA
COAD -0.089
HGSC 1.572
ccRCC -1.101
GBM
HNSC -0.535
LUAD
LUSC 0.153
non_ccRCC
PDAC
UCEC
STAT3-Tyr705
Cancer Intensity
BRCA 0.868
COAD
HGSC
ccRCC
GBM 0.383
HNSC
LUAD -0.032
LUSC
non_ccRCC -1.398
PDAC 1.121
UCEC -0.942

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - A Renal cell carcinoma Acetylation 31201813
- - C Glioblastoma Phosphorylation 24135280
- - D Breast cancer Acetylation 30365149
- - P Retinoblastoma Ubiquitination 35980647
- - P Skin cancer Phosphorylation 24460316
- - P Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 24132924
- - P Liver cancer Phosphorylation 23460367
- - P Sarcoma Phosphorylation 15010843
- - P Ovarian cancer/carcinoma Phosphorylation 15010843
- - P Colon cancer/carcinoma Phosphorylation 23335526
- - U Gastric cancer Phosphorylation 24116074
- - U Hepatocellular carcinoma Acetylation 37792308
- - U Pancreatic cancer Ubiquitination 33123271
- - U Non-small cell lung cancer Ubiquitination 30881015
- - U Colitis Phosphorylation 11181699
- - U Neuroblastoma Phosphorylation 15715521
- - U Bladder cancer Phosphorylation 15034568
- - U Crohn's disease Phosphorylation 11181699
- - U Ulcerative colitis Phosphorylation 11181699
- - U Breast cancer/tumor/carcinoma Phosphorylation 10853013
- - U Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 10853013
- - U Precancerous lesion of gastric cancer Phosphorylation 23596790
- - U Endometrial cancer/carcinoma Phosphorylation 24321270
- - U Bladder cancer Phosphorylation 23526079
- - U Colorectal cancer Phosphorylation 33982216
- - U Triple-negative breast cancer Phosphorylation 34408002
- - U Small cell lung cancer/carcinoma Phosphorylation 22938476
- - U Oral squamous cell carcinoma Phosphorylation 35562900
- - U Pancreatic cancer Phosphorylation 37443111
- - U Psoriasis Phosphorylation 28901004
- - U Gastric cancer Phosphorylation 36769245
- - U Triple-negative breast cancer Phosphorylation 37095176
- - U Non-small cell lung cancer Phosphorylation 36372977
- - U Gastric cancer Phosphorylation 35087591
- - U Hepatocellular carcinoma Phosphorylation 37178251
- - U Osteosarcoma Phosphorylation 32549792

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: